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Background: Differences in 5-hydroxymethylcytosine, 5hmC, distributions may complicate previous observations
of abnormal cytosine methylation statuses that are used for the identification of new tumor suppressor gene
candidates that are relevant to human hepatocarcinogenesis. The simultaneous detection of 5-methylcytosine and
5-hydroxymethylcytosine is likely to stimulate the discovery of aberrantly methylated genes with increased
accuracy in human hepatocellular carcinoma.
Results: Here, we performed ultra-performance liquid chromatography/tandem mass spectrometry and single-base
high-throughput sequencing, Hydroxymethylation and Methylation Sensitive Tag sequencing, HMST-seq, to synchronously
measure these two modifications in human hepatocellular carcinoma samples. After identification of differentially
methylated and hydroxymethylated genes in human hepatocellular carcinoma, we integrate DNA copy-number alterations,
as determined using array-based comparative genomic hybridization data, with gene expression to identify genes that are
potentially silenced by promoter hypermethylation.
Conclusions: We report a high enrichment of genes with epigenetic aberrations in cancer signaling pathways. Six genes
were selected as tumor suppressor gene candidates, among which, ECM1, ATF5 and EOMES are confirmed via siRNA
experiments to have potential anti-cancer functions.Background
Hepatocellular carcinoma (HCC), which is frequently
caused by hepatitis virus (B and C) infection and alcohol
abuse, is the most common type of primary liver cancer
and third leading cause of cancer death worldwide [1,2].
Although surgical and chemotherapeutic treatment of
HCC is evolving, surgical resection remains the treatment
of choice for many patients. Surgical resection for HCC
patients is associated with a 5-year survival rate of 50%;
however, there is a 70% recurrence rate [3].* Correspondence: flys828@gmail.com; huangjchgc@hotmail.com
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unless otherwise stated.The mechanism underlying HCC development remains
poorly understood. It is widely accepted that accumulating
genetic alterations such as chromosomal alterations, gene
amplifications, and mutations are associated with HCC
[4,5]. Furthermore, epigenetic alterations, particularly ab-
normal DNA methylation at the 5 position of cytosine
(5mC), have been extensively studied [6]. DNA hypome-
thylation in cancer cells is thought to lead to chromo-
somal instability and oncogene activation [7] and has
generally been regarded as a highly stable clinical marker
for cancer [8]. More importantly, a number of studies have
reported that the hypermethylation of tumor suppressor
genes (TSGs) contributes to HCC pathogenesis [9-11].
Thus, the accurate detection of DNA methylation may
provide powerful mechanistic insight into hepatocarcino-
genesis and may have a potential application for the clin-
ical diagnosis of HCC.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gao et al. Genome Biology 2014, 15:533 Page 2 of 13
http://genomebiology.com/2014/15/12/533However, the differences in 5-hydroxymethylcytosine
(5hmC) distributions may complicate previous observa-
tions regarding abnormal cytosine methylation status.
Previous technologies, such as bisulfite treatment and
restriction enzyme-based technologies, are unable to dis-
tinguish between 5mC and 5hmC [12,13], and the exist-
ence of 5hmC in samples reduces the accuracy of DNA
methylation detection [14]. 5hmC is catalyzed by ten-
eleven translocation (TET) proteins, which first convert
5mC to 5hmC, then to 5-formylcytosine (5fC) and fi-
nally to 5-carboxylcytosine (5caC), thereby may play a
role in DNA demethylation [15,16]. 5hmC was found to
be abundant in embryonic stem cells and neurons, but it
is greatly reduced in tumor cells [15,17-20], including
HCC cells [21].
Therefore, there is a renewed interest for the simultan-
eous detection of 5mC and 5hmC in the context of gen-
omic profiling studies, which may stimulate the discovery
of aberrantly methylated genes with increased accuracy in
HCC cells. Till now, the number of known aberrantly
promoter-methylated genes is fewer for HCC than for
colon and gastric cancer [5,6]. Furthermore, a more com-
prehensive study of the 5hmC status in HCC is required
to determine its role in hepatocarcinogenesis.
To fully examine 5mC and 5hmC status in HCC, we
used ultra-performance liquid chromatography/tandem
mass spectrometry (UPLC-MS/MS) and a newly devel-
oped single-base high-throughput sequencing approach
(hydroxymethylation and methylation sensitive tag se-
quencing (HMST-seq)) to synchronously measure these
two modifications in HCC samples and their adjacent
non-cancerous liver tissues (non-HCCs). We report a
global loss of 5hmC and key genes containing altered
methylation or hydroxymethylation that are enriched
for important cancer-relevant signaling pathways. In
particular, we identified three new genes (ECM1, ATF5,
and EOMES) with potential anti-cancer functions that
may promote the understanding of the molecular
mechanisms of HCC development and progression and
potentiate the future clinical applications of 5hmC
detection.
Results
Globally increased 5mC but decreased 5hmC levels at
genomic CCGG loci in HCC
We first performed UPLC-MS/MS to investigate global
5mC and 5hmC levels in 16 pairs of HCC and non-HCC
samples and two HCC cell lines (97 L and LM6 cells).
We found that both 5mC and 5hmC were frequently
decreased in 71% and 100% of the HCC specimens,
respectively, compared with non-HCC specimens. Cor-
respondingly, 5mC and 5hmC levels in the two HCC
cell lines remained relatively low (Additional file 1:
Tables S2). These results are in accordance withprevious reports of a global loss of 5mC and 5hmC in
HCC and other cancer types [18,20,21].
To further examine the distribution of 5mC and 5hmC
in HCC specimens and cell lines, we applied a newly de-
veloped technology, ‘HMST-seq’ [22], on seven of the 16
pairs of HCC specimens and the two cell lines. HMST-seq
can detect 5mC and 5hmC at ‘CCGG’ sites with a single-
base resolution, in which three different libraries were
constructed for each sample including a library containing
unmodified C, mC, and hmC tags through MspI-mediated
digestion of normal genomic DNA, a library containing C
and mC tags through MspI-mediated digestion of glucosy-
lated genomic DNA and a library containing only C tags
through HpaII-mediated digestion of normal genomic
DNA [22]. During manual examination of the tag distribu-
tion of these three libraries, we filtered out samples with
similar distributions of ‘C +mC’ tags and ‘C’ tags, which
indicate potential insufficient MspI-mediated digestion of
glucocylated genomic DNA (Additional file 2: Figure S1).
As a result, three out of the seven matched pairs of HCC
and non-HCC specimens passed our quality control. We
then used these three matched pairs of specimens to infer
methylation and hydroxymethylation status across all
CCGG sites. On average, 170 million reads for each library
were generated, and 147 million (86.58%) reads were
aligned to a virtual library of the human genome (see the
Methods section). An average of 100 M (58.93%) uniquely
aligned reads were then obtained for each library, resulting
in a minimum of 1.3 M informative ‘CCGG’ sites with
greater than 50 X sequencing depth for each sample
(Additional file 1: Table S3). Data normalization for the
three libraries was performed, and significantly modified
sites with 5mC or 5hmC were identified with our estab-
lished methods (sequencing depth >10 X, FDR <0.001)
[22]. On average, 433,045 (31.49%) and 72,080 (5.24%)
total examined CCGG sites were identified as significant
for 5mC and 5hmC, respectively, in non-HCC specimens.
In addition, increased 5mC (471,270; 34.72%) but de-
creased 5hmC (66,020; 4.89%) was observed in the HCC
specimens (Additional file 1: Table S2).
Based on these data, a broad distribution of 5mC and
5hmC was observed (Figure 1). Compared with the back-
ground distribution of all ‘CCGG’ sites in the genome,
5mC was more deficient in regulatory regions such as en-
hancers or regions surrounding transcriptional start sites
(TSS) but relatively enriched in exons and intragenic re-
gions. In contrast, the distribution of 5hmC was more
evenly distributed with a background distribution across
all ‘CCGG’ sites (Additional file 2: Figure S2). In agree-
ment with previous reports that CpG islands are hyper-
methylated in tumors [8], globally increased 5mC was
observed in CCGG sites across the genome of HCC com-
pared with non-HCC samples (Figure 1A). In contrast,
5hmC levels of CCGG sites across the HCC genome were
AB
C
Figure 1 The relative density of 5mC and 5hmC within genomic regions. (A) The relative density indicates the ratio between 5mC or 5hmC and
all inspected ‘CCGG’ sites within each genomic region. (B) The relative mRNA levels of UHRF1, TET1, 2, and 3 in HCCs and adjacent non-HCC liver
tissues tested by RT-qPCR. (C) The expression of TET2 and UHRF1 protein in HCCs and adjacent non-HCC liver tissues using western blot. β-actin was
used as loading control.
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crease tested by UPLC-MS/MS.
As TET proteins are responsible for oxidizing 5mC to
5hmC [15,16], we tested mRNA levels of TET1, 2, and 3
in nine pairs of HCC specimens. We found downregula-
tion of mRNA levels of TET1 and TET2, but not TET3, in
HCCs in comparison with non-HCC samples (Figure 1B).
Consistent with its mRNA level, TET2 protein was con-
firmed downregulated in HCCs as well (Figure 1C). We
also tested UHRF1 as its protein helps to recruit DNMT1
to hemi-methylated DNA to facilitate faithful maintenance
of DNA methylation [23]. In contrast to TET genes, both
mRNA and protein expression levels of UHRF1 gene were
highly upregulated in HCCs (Figure 1B and C), consistent
with previous reports in various types of cancers [24].
Based on these results, expression level changes of keyenzymes or cofactors that are involved in DNA methyla-
tion/hydroxymethylation regulation might be correlated
with 5mC increase and 5hmC decrease in CCGG sites
across the HCC genome.
DMRs and DhMRs are revealed by inter-group
comparisons
Based on the observation of global methylation and
hydroxymethylation alterations, we next aimed to specify
differentially methylated regions (DMRs) and differentially
hydroxymethylated regions (DhMRs) between HCC and
non-HCC samples. A sliding window strategy was used
for inter-group comparison of the HCC and non-HCC
groups as previously described [22]. To identify differen-
tially modified regions containing at least five CCGG sites
(Wilcoxon rank-sum test, P <0.05), we began with the
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DhMRs (Additional file 1: Table S4, S5). Although both
modifications were widely distributed across the genome,
DMRs occurred more frequently at proximal regions close
to TSSs, while DhMRs were more likely to occur at distal
sites upstream of TSSs (Figure 2A and B). Thus, only 10
(4.12%) DhMRs overlapped with DMRs, suggesting that
changes in these two modifications rarely co-occur.
Furthermore, we compared the 5mC and 5hmC levels of
the DMRs and DhMRs, respectively, among HCC and non-
HCC samples and two HCC cell lines (97 L and LM6). 97 LA
B
Figure 2 The distribution of DMRs and DhMRs. (A) The distribution of D
located in two different elements, are attributed to regions that overlap wi
(B) The distance between DMRs and DhMRs and transcriptional start sites (
TSSs are displayed throughout regions of 40 kb upstream and downstream
DMRs or DhMRs. The x-axis shows the P value from hypergeometric test adand LM6 were derived from the same HCC patient but ex-
hibit highly different metastatic potentials [25]. Similar to
the HCC samples, hypermethylation of the DMRs and
hypohydroxymethylation of the DhMRs were observed in
97 L and LM6 compared with non-HCC cells. Notably, the
LM6 cells, which have a higher metastatic potential, exhib-
ited a slightly higher methylation level in the DMRs com-
pared with 97 L cells (Additional file 2: Figure S3).
To replicate above results, we re-performed HMST-
Seq library construction on two pairs of the samples that
first failed our quality control. Similar data quality andC
MRs and DhMRs within genomic regions. The DMRs and DhMRs,
th a bigger proportion of the DMR or DhMR and counted only once.
TSSs). The densities of DMRs and DhMRs with different distances from
from TSSs. (C) KEGG pathway enrichment analysis of genes related to
justed by the multiple test adjustment.
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Table S2, S3). By combining all qualified data, an inter-
group comparison of five matched pairs of HCC and
non-HCC samples was re-performed, resulting in a total
of 5,126 DMRs and 571 DhMRs using the same
window-sliding strategy (Additional file 1: Table S4, S5);
similar results regarding the distribution of DMR and
DhMR were observed (Figure 2A, B).
Enrichment of genes containing DMRs and DhMRs in
cancer-related pathways
To further address the functional effects of DNA modifi-
cation changes in HCC, we first performed KEGG path-
way enrichment analysis (see the Methods section) of
1,373 DMR and 218 DhMR genes from the three
matched pairs of HCC and non-HCC samples, respect-
ively. A higher enrichment rate for DMR (16.8%; 231 out
of 1373) than DhMR genes (8.7%, 19 out 218; FDR
<0.05) was found (Additional file 1: Table S6). Although
DMR and DhMR genes were enriched in KEGG cancer
and metabolic pathways (Figure 2C), these genes rarely
overlapped (Additional file 2: Figure S4). In addition, en-
richment analysis of 3,283 DMR and 651 DhMR genes
from the five pairs of HCC and non-HCC samples, re-
spectively, revealed similarly enriched pathways (data
not shown). Notably, cancer-related pathways including
‘Pathways in cancer’, ‘Focal adhesion’, ‘Wnt signaling
pathway’, and ‘MAPK signaling pathway’ were enriched
for DMR genes.
Focal adhesion components are crucial for the cell
growth, movement, differentiation, and tailoring of the
extracellular microenvironment [26], and of these genes,
focal-adhesion kinase (FAK) is an important mediator
involved in cancer formation and progression [27]. Mul-
tiple genes that encode extracellular proteins and trans-
mit signals, including extracellular matrix (ECM),
integrin, SRC, and growth factor (GF) genes, were
hypermethylated in HCCs. Signaling by the Wnt family
of secreted glycolipoproteins via the transcriptional co-
activator β-catenin can also determine cell fate and has
been implicated in cancer proliferation and survival, in-
cluding HCC cells [28]. Aberrant methylation was also
observed for key genes of the Wnt signaling pathway in-
cluding the Wnt, FZD, and APC genes. Furthermore,
multiple key genes in the MAPK signaling pathway were
enriched among those containing DMRs, including
TGFB2, EGFR, NFkB2, and p38 mitogen-activated pro-
tein kinase (Figure 3, Additional file 1: Table S6).
DMR genes were also enriched in metabolic pathways,
which are also relevant. In particular, one gene, PKLR,
was aberrantly methylated in HCC; PKLR encodes a
pyruvate kinase and is involved in the glycolysis process
and important for cancer metabolism and tumor growth,
[29,30]. In summary, these results suggest that abnormalDNA methylation and gene hydroxymethylation might
be crucial participants in important cancer-related path-
ways in HCC.
Transcriptional changes in key genes in cancer pathways
are revealed by integration of multi-omics data
To reveal potential complications resulting from DNA
modification changes on gene transcription, we further
performed transcriptome profiling of the seven pairs of
HCC samples and two HCC cell lines using RNA-Seq
and Affymetrix microarray technologies. Based on the
high-quality data, we performed pair-wise comparisons
to identify differentially expressed genes (DEGs) in the
seven pairs of HCC samples. Copy number variation
(CNV) analyses were then used to address transcription
changes due to gene CNVs (see the Methods section). If
significantly upregulated genes were revealed through
gene amplification in the HCC samples, we filtered out
those DEGs. In addition, significantly downregulated
genes resulting from gene deletion in the HCC samples
were also removed. As a result, 5,848 upregulated and
1,586 downregulated DEGs in the HCC samples were
identified (Additional file 1: Table S7). Furthermore, we
examined the transcription level of these DEGs in the
two HCC cell lines and found that most of these genes
had a similar expression level as in the HCC samples
but differed substantially from the non-HCC samples
(Additional file 2: Figure S5).
Based on these data, we then examined key genes in
the three cancer-related pathways that were enriched in
the DMR genes (focal adhesion, Wnt, and MAPK). Not-
ably, the FAK (PTK2), β-catenin (CTNNB1), and p38
MAPK (MAPK12) genes were all significantly upregu-
lated in HCC. In particular, genes downstream of p38
MAPK including MAPKAPK2, NFkB2, p53, CHOP
(DDIT3), MSK (RPS6KA4), CREB (ATF4), and c-Myc,
were all upregulated, indicating activation of these sig-
naling pathways in the HCC specimens (Figure 3).
TSG candidate screening
To screen TSG candidates that might be aberrantly reg-
ulated by DNA methylation, we cross-matched the se-
lected DEGs with genes that contained DMRs or
DhMRs within 5 kb upstream of their TSS. As 5hmC is
generated by TET proteins via oxidizing 5mC [15,16],
we further required that hypermethylated genes should
be hypohydroxymethylated and vice versa, hypomethy-
lated genes should be hyperhydroxymethylated. As a re-
sult, expression levels of 124 DMR genes were negatively
correlated with their methylation levels, while 22 DhMR
genes were positively correlated between their expres-
sion and hydroxymethylation levels, in the three
matched pairs. Majority (85) of the 124 DMR genes
overlapped with the gene set identified in the five
Figure 3 Genes in cancer-related pathways. Genes in the ‘Focal adhesion’, ‘Wnt signaling pathway’ and ‘MAPK signaling’ pathway. The cyan
rectangle indicates differentially expressed genes (DE genes), and the red rectangle indicates genes with a differentially methylated region
(DMR gene).
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genes were replicated between the two comparison
groups (Additional file 2: Figure S6). These results might
indicate that DMRs are more stable than DhMRs in
HCC populations. Based on these data and on reports in
the literature, which indicated that the biological func-
tion of these genes is relevant to liver development or
disease, we selected 18 candidate genes for further
validation.
Semi-quantitative RT-PCR was then used to detect the
mRNA levels of the 18 genes in 20 additional pairs of HCC
and non-HCC specimens (Primer sequences listed in
Additional file 1: Table S8). Among the 18 genes, six
genes including FAM150A, TCF21, EOMES, ATF5, DPT,
and ECM1 were frequently downregulated in 85%, 85%,
35%, 60%, 50%, and 60% of the 20 HCC samples,
respectively, compared with non-HCC samples (Additional
file 2: Figure S7). As all six of these genes only contained
DMRs in their promoters, but not DhMRs, bisulfite se-
quencing can then efficiently validate DNA methylationchanges for these genes. Therefore, we first performed bi-
sulfite sequencing PCR (BSP) on three selected DMR genes
(FAM150A,TCF21, and EOMES) in the three pairs of HCC
samples for technical validation. The results confirmed sig-
nificant differential methylation between HCC and non-
HCC samples for each gene, indicating the accuracy of
DMR detection by HMST-seq (Additional file 2: Figure S8,
Additional file 1: Table S9). Based on these results, we fur-
ther validated five selected DMR genes (ATF5, ECM1,
EOMES, FAM150A, and TCF21) in 20 additional pairs of
HCC and non-HCC samples for biological replication. A
high-throughput illumina-sequencing-based BSP method
that we developed recently was applied [31] (See Methods).
Our results confirmed consistently higher methylation levels
of all these genes in HCC samples in comparison with non-
HCC samples (Figure 4A, Additional file 1: Table S9). In
particular, ECM1 and TCF21 displayed significant differen-
tial methylation between HCC and non-HCC groups
(P <0.05). Besides of key hypermethylated gene promoters,





Figure 4 The effect of siRNA knockdown on hepatocellular carcinoma cell growth. (A) Validation of DNA methylation for biological replication
(blue box indicate non-HCC and red box indicate HCC samples). Growth curve of YY8103 and QGY7701 cells treated with siRNA-NC, (B, C) ATF5-siRNA1
and ATF5-siRNA2, (D, E) ECM1-siRNA1 and ECM1-siRNA2, and (F) EOMES-siRNA1 and EOMES-siRNA2. The expression of genes was analyzed using both
qRT-PCR and western blot.
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hydroxymethylation tested by UPLC-MS/MS, the methyla-
tion levels of these repetitive elements tested by bisulfite
sequencing were significantly lower in HCC samples
(Figure 4A).
Suppression of endogenous ATF5, ECM1, and EOMES
promotes HCC cell line proliferation
To evaluate the potential contribution of the six target
genes to HCC tumorigenesis, we next aimed to perform
gene knockdown experiments in HCC cell lines. By evalu-
ating the expression level of six target genes in available
HCC cell lines using RT-PCR, we selected YY8103 and
QGY7701 HCC cell lines, as in which ATF5, EOMES, and
ECM1 were all expressed. However, FAM150A, TCF21,
and DPT were hardly expressed in almost all cell lines
(Additional file 2: Figure S7). Based on these results, we
designed two specific siRNAs against each gene of ATF5,
EOMES, and ECM1 (Additional file 1: Table S10) for
knockdown experiments, using siRNA-NC as a negative
control. Our data showed that the expression of these
three endogenous target genes was efficiently knockeddown in YY-8103 and QGY7701 cells by these siRNAs, as
demonstrated through both real-time PCR assays and
western blots (Figure 4B, C, D, E, and F). As a result, the
transient transfection of siRNA1 and siRNA2 for these
three genes enhanced the growth of YY8103 and
QGY7701 HCC cells compared with cells transfected with
siRNA-NC (P <0.05; Figure 4). Furthermore, analysis of
colony formation in soft agar confirmed that among the
four target genes, silencing ATF5, ECM1, and EOMES sig-
nificantly promoted the anchorage-independent growth of
YY-8103 and QGY7701 cells compared with the siRNA-
NC control cells (P <0.05; Figure 5).
Taken together, these data support the hypothesis that
knockdown of ATF5, ECM1, and EOMES consistently
promoted the growth of existing HCC cells, suggesting
that silencing these three genes may contribute to HCC
oncogenesis and progression.
Discussion
Previous studies have shown that hypermethylation of mul-
tiple TSGs contributes to HCC pathogenesis and represents























































































































Figure 5 siRNA knockdown affects anchorage-independent cell growth. Anchorage-independent colony formation of YY8103 and/or QGY7701
cells treated with siRNA-NC, and (A) ATF5-siRNA1 and ATF5-siRNA2, (B) ECM1-siRNA1 and ECM1-siRNA2, (C) EOMES-siRNA1 and EOMES-siRNA2. The
results showed that knockdown of the three genes including ATF5, ECM1, and EOMES can increase the Anchorage-independent colony formation.
Original magnification is × 100.
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additional dimension of complexity to the methylation al-
terations observed in cancer. Most previous studies have
used bisulfite treatment or methylation-sensitive enzyme
digestion-based methods to investigate novel DNA methy-
lation biomarkers, which cannot distinguish 5-hmC from5-mC [12,13]. In addition to the heterogeneity of cancer
samples or technological differences, inaccurate quantifica-
tion of DNA methylation levels might also lead to incon-
sistent or even contradictory results between different
studies [33]. Thus, distinguishing between 5hmC and 5mC
assists in the identification of DNA methylation biomarkers
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specificity.
Here, we applied a multi-omics strategy to vertically in-
tegrate epigenomic, genomic, and transcriptomic profiling
to screen for novel epigenomic biomarkers and TSG can-
didates of HCC. We applied both the commonly used
UPLC-MS/MS and the newly developed HMST-Seq tech-
nologies to simultaneously examine DNA methylation
and hydroxymethylation levels. Globally, 5mC and 5hmC
levels were reduced in HCC, as confirmed by UPLC-MS/
MS. As HMST-Seq can only test CCGG MspI sites, an in-
creasing amount of 5mC was observed for CCGG sites, in
contrast to whole genome 5mC tendency. This result not
only reflects the limitation of HMST-Seq in detection of
global 5mC pattern, but also indicates an uneven distribu-
tion of 5mC in the genome. On the other hand, as 5hmC
were evenly distributed across the genome, consistently
low levels of 5hmC across the genome-wide CCGG MspI
sites were also observed. Furthermore, DMRs and DhMRs
rarely co-occurred at the same genomic region. These re-
sults might support the hypothesis that 5hmC is an inter-
mediate of the demethylation process [15,16], and loss of
hydroxymethylation might be also an epigenetic feature of
HCCs [21].
We found that a significant number of DMR genes were
enriched in several highly interrelated cancer signaling
pathways, including the ‘Focal adhesion’, ‘Wnt’, and ‘MAPK’
pathways (Figure 2C). Furthermore, the activation of key
signaling pathway genes, including FAK in ‘Focal adhesion’,
β-catenin in ‘Wnt’, and p38 and its downstream genes in
‘MAPK’, indicated the activation of these signaling pathways
in HCC, which has been previously reported in HCC. Al-
though we currently have no direct evidence that the
methylation and hydroxymethylation changes in DMR and
DhMR genes may directly contribute to the activation of
these pathways, these two types of DNA modifications rep-
resent essential participants in heptocarcinogenesis. In
addition to gene transcription repression, DNA modifica-
tions may also be important for alternative splicing [34],
gene mutation [35], and chromatin remodeling [36] in
tumorigenesis. Further studies are needed to examine these
genes.
In addition to the genes found enriched by KEGG path-
way analysis, we confirmed that the suppression of three
novel genes by promoter hypermethylation can significantly
enhance cell growth and progression in HCC cell lines, in-
dicating their potential as TSG candidates. These three
genes have never been reported in previous studies on aber-
rant DNA methylation of HCCs [6,9,11,32]. Of these three
genes, ECM1 has been reported to inhibit the activity of
matrix metalloproteinase 9 (MMP9) through high-affinity
protein/protein interactions [37]. Due to the significant
downregulation of ECM1 transcription, our data also sup-
port the significant upregulation of MMP9 transcription inHCC, which agrees with previous observations of highly up-
regulated MMP expression in many solid tumors [38].
MMPs are key modulators of the tumor microenvironment,
and it has been shown that MMPs not only regulate ECM
turnover but also cell signaling pathways controlling cell
growth, inflammation and angiogenesis in a non-proteolytic
manner through various non-catalytic domains [38].
ATF5 is a highly abundant liver-enriched transcription
factor that belongs to the ATF/cAMP response element-
binding family [39]. A study has indicated that transcrip-
tional expression of ATF5 is directly induced by CHOP
and ATF4, which together with ATF5 form the inte-
grated stress response (ISR) pathway that is critical for
alleviating damage accrued during acute stress [40].
Thus, the proapoptotic functions of ATF5 and CHOP
have been revealed [40]. In HCC, although CHOP was
activated, ATF5 was hypermethylated in its promoter
and exhibited downregulated transcriptional expression.
These results are in agreement with previous studies
that confirmed downregulation of ATF5 transcription
[41] and protein expression levels [42] in HCC. There-
fore, ATF5 might be blocked in HCC, resulting in anti-
apoptotic effects and cancer cell survival.
The T-box transcription factor eomesodermin (EOMES)
has been found to have a regulatory role for CD8 T cell ac-
tivity in humans [43] and plays a critical role in tumor im-
mune surveillance and eradication [44]. The absence of
EOMES in tumor-infiltrating lymphocytes correlates with
enhanced lymph node metastasis in colorectal cancer [43].
Conclusions
In summary, ECM1, ATF5, and EOMES may all serve as
novel TSGs that are aberrantly hypermethylated at their
promoters leading to their downregulated transcription,
which results in HCC tumorigenesis and progression. In
addition, we have identified three other genes (FAM150A,
TCF21, and DPT) with promoter hypermethylation and
significant transcriptional downregulation in HCCs. These
six genes may comprise a gene panel that could be used
for the clinical diagnosis and prognosis of HCCs with re-




All HCC tissue specimens were obtained from patients
who underwent surgical resection for their tumors and
provided informed consent prior to liver surgery. The pri-
mary tumor specimens were immediately frozen at -80°C
until DNA/RNA extraction. Specimens (approximately
1 cm3) of the tumor and adjacent liver tissue were
collected from each patient, and the HCC diagnosis was
confirmed through pathological examination. The HCC
specimens used in this study were grouped according to
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Steiner grading system. The clinical characteristics of the
patients and tumors are summarized in Additional file 1:
Table S1. This project and protocols involving human and
animal tissues were approved by the ethics committee of
the Research Ethics Committee of Shenzhen Third Peo-
ple’s Hospital (No. 2012-010), and conducted according to
the Declaration of Helsinki. The use, for research pur-
poses, of tumor tissues from clinically surgical removal
was deemed exempt from a requirement for informed
consent beyond the consent normally obtained for this
clinical procedure.
Normal liver (including LO2 and WRL68) and HCC cell
lines (including Hep3B, SK-hep1, Focus, Huh7, SMMC7721,
MHCC97L, MHCC97H, MHCC-LM3, MHCC-LM6, PLC,
HepG2, YY8103, QGY7701, QGY7703, BEL7402, BEL7404,
and BEL7405) were also used in this study. Of these cell
lines, Hep3B, SK-hep1, Focus, Huh7, SMMC7721, PLC,
HepG2, YY8103, QGY7701, QGY7703, BEL7402, BEL7404,
and BEL7405 were obtained from a commercial source
(Institute of Chemistry and Cell Biology at Shanghai). In
addition, the MHCC97L, MHCC97H, MHCC-LM3, and
MHCC-LM6 cell lines were derived from published
references [45,46] and were kindly provided by professor
Yinkun Liu from the Liver Cancer Institute affiliated with
Zhongshan Hospital in Shanghai.
DNA and RNA extraction and cDNA synthesis
Genomic DNA was extracted from all samples using the
DNeasy Tissue kit (Qiagen, Valencia, CA, USA), accord-
ing to protocols recommended by the manufacturer.
Total RNA was extracted from the HCC cell lines and
frozen tissue samples, which were pulverized in liquid
nitrogen using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). To reduce the risk of genomic DNA contamin-
ation, 1 to 2 μg RNA was incubated with 2 U DNase I
(Invitrogen, Carlsbad, CA, USA), 1 μL DNase buffer
and, 0.4 μL RNase Out for 15 min at room temperature.
The RNA concentration was determined by spectropho-
tometry, and the total RNA integrity was examined by
visualization of the 28S and 18S ribosomal RNAs in a
1.2% agarose gel. First-strand cDNA was synthesized
using the PrimeScript RT Reagent Kit (TaKaRa, Otsu,
Japan) according to the manufacturer’s instructions.
UPLC–MS/MS analysis
Genomic DNA (0.2 μg) extracted from all patients and cell
lines was digested with 1 U DNase I, 2 U alkaline phosphat-
ase, calf intestinal, and 0.005 U snake venom phospho-
diesterase I at 37°C for 24 h. A microcon centrifugal filter
device with a 3,000 D cutoff membrane was used to remove
protein from the digested DNA samples by centrifuging at
12,000 rpm for 60 min. The mobile phase consisted of 0.1%
formic acid (solvent A) and methanol containing 0.1%formic acid (solvent B). The flow rate was set to 500 μL/
min. The enzymatically digested DNA samples (5 μL each)
were injected for UPLC-MS/MS analysis with a LC gradient
as follows: 0.0-4.0 min, 0 to 50% of solvent B; 4.0-6.0 min,
50% solvent B; 6.0-6.1 min, 50% to 5% of solvent B; and 6.1-
15 min, 5% of solvent B. The separated analytes were de-
tected using a 5500 Qtrap linear ion trap quadrupole mass
spectrometer equipped with a Turbo V ion source operated
in the ESI mode (AB Sciex) with Analyst software (Version
1.5). The Source and Gas were set as follows: gas 1, nitrogen
(45 psi); gas 2, nitrogen (40 psi); ion spray voltage, 5,500 V;
ion source temperature, 400°C; and curtain gas, nitrogen
(30 psi). The mass spectrometer was operated in the multi-
reaction monitoring mode (MRM).
Data analysis for HSMT-Seq
Genomic DNA was extracted from all patients and cells
using the QIAamp DNA Blood Mini Kit (Qiagen). HSMT-
Seq library construction was performed following our previ-
ously reported protocol [22]. The libraries were sequenced
using single-end 50 bp sequencing strategy with an Illumina
HiSeq2000 sequencing system. The FASTQ sequence reads
were mapped to a virtual human reference library (hg19)
with no more than one mismatch after adapter removal and
low-quality read filtering. The virtual library was constructed
as follows. The human reference genome (hg19) was in
silico digested with MspI and NlaIII, and we defined the
DNA sequences between the nearest NlaIII sites around
each MspI site in both directions as the virtual library refer-
ence for mapping. Unambiguous mapped tags were used for
further analysis. The data for three libraries were normalized
according to a previous method (Global Rank-invariant Set
Normalization, GRSN) [47] based on the normalized tag
counts, and the modification abundance of a specific CCGG
site was determined as the ratio between the tag counts of
two libraries. For instance, the hydroxymethylation level can
be defined as the ratio between ‘C+mC+hmC’ and ‘C+
mC’ tags. Furthermore, CCGG sites with significantly differ-
ent tag counts (sequencing depth >10X, FDR <0.001) based
on Poisson distribution with a ratio of tags between two li-
braries larger than 1 were determined to be significantly
modified sites.
For a given genomic interval, the modification frequency
of CCGG sites was defined as the ratio of significantly modi-
fied sites within all CCGG sites. Differentially methylated or
hydroxymethylated regions (DMR or DhMR) between HCC
and non-HCC samples were defined in the following steps:
(1) The first five CCGG sites containing at least four CCGG
sites with the same changing trend and a Wilcoxon rank-
sum test P value <0.05 as a seed site for candidate DMRs
was used; (2) a 3’ downstream adjacent CCGG with the
same changing trend was then incorporated with this candi-
date DMR. Up to a 2,000-bp inter-distance was allowed be-
tween the two adjacent CCGGs, and a Wilcoxon rank-sum
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these steps until the Wilcoxon rank-sum test P value
is ≥0.05; and (4) the incorporated region was defined
as a DMR or DhMR.
Enrichment analysis
Functional enrichment analysis for genes with DMRs or
DhMRs was performed using WebGestalt [48,49], which
is freely accessible at [50].
Data analysis for differentially expressed genes (DEGs)
The gene expression levels based on RNA-seq and Affy-
metrix microarray data were measured by the reads per
kilobase of transcript per million reads (RPKM) and tags
per million reads (TPM) algorithm, respectively. The dif-
ferentially expressed genes (DEGs) were identified in the
five pair-wise samples with Affymetrix microarray data
by Wilcoxon rank-sum test and in each of the two pair-
wise samples with RNA-seq data according to a previ-
ously published method [51]. Genes that were signifi-
cantly expressed (FDR <0.05) in at least one group and
regulated similarly in all the groups were further identi-
fied as differentially expressed genes (DEGs).
Illumina-sequencing-based BSP
Illumina-sequencing-based BSP was performed based on a
previously described strategy with minor adjustment [31].
PCR primers were designed using online software [52] and
then concatenated 22 bp common sequences at their 5’
end, respectively, which would mediate high throughput
sequencing linker extension during the following PCR
procedure. All PCR products were about 500 bp. For the
high throughput bisulfite-amplicon library construction
using large scale of clinical samples, WaferGen Biosystem
(WaferGenBiosystems) was employed. Briefly, 500 ng of
genomic DNA extracted from whole blood were converted
using EZ DNA Methylation-Gold Kit™ (ZYMO). For each
sample, bisulfite converted genomic DNA, KAPA2G Ro-
bust HotStart ReadyMix (KAPA Biosystems), PCR primers,
PCR primers mediated high throughput sequencing linkers
with a barcode sequence were dispensed into one individual
nanowell of a Smart MyDesign Chip, which contains 5,184
nanowells, by Smart Chip Multisample Nanodispenser.
Thirty-six amplicons for each sample and 150 samples
could be constructed as one library with barcode sequence
classifying samples using one Smart MyDesign Chip. PCR
amplification of Smart MyDesign Chip was conducted
using the Techne Prime Thermal Cycler. PCR product was
purified using the QIAquick Gel Extraction Kit (Qiagen).
After analyzed by an Agilent 2100 Bioanalyzer (Agilent
Technologies) and quantified by real-time PCR, the library
was sequenced with pair end 250 bp using Illumina Miseq
sequencer.Semi-quantitative RT-PCR
Reverse transcription (RT) was performed with 2 μg of
total RNA treated with RNase-free DNase I. Semi-
quantitative RT-PCR was then performed using primers
for target genes (Additional file 1: Table S8). The length
of the amplified fragments was 350 bp, and β-actin
served as an internal reference. The primers for β-actin
were as follows: 5′-TCACCCACACTGTGCCCATC
TACGA-3′ (forward) and 5′-CAGCGGAACCGCT
CATTGCCAATGG-3′ (reverse). The length of the β-
actin amplicon was 295 bp. The PCR products were sep-
arated in 2% agarose gels containing ethidium bromide.
The PCR reactions were performed in a volume of 20 μL
using the TaKaRa PCR Kit. The reactions were per-
formed at 94°C for 5 min followed by 30 to 35 cycles
(for 18 target genes) or 25 cycles (for β-actin) at 94°C
for 30 s, 55°C for 30 s, and 72°C for 30 s with a final ex-
tension at 70°C for 5 min. The PCR products were
brought to 4°C at the end of the reaction, and they were
then separated in 2% agarose gels containing ethidium
bromide.
Western blot
Cells were collected using a 2× loading lysis buffer (2×
concentrations: 50 mmol/L Tris-HCl, pH 6.8, 2% sodium
dodecyl sulfate, 10% 2-mercaptoethanol, 10% glycerol,
and 0.002% bromophenol blue). Total protein extracts
from cultured cells were subjected to protein gel electro-
phoresis using 12% SDS-PAGE, transferred to a Hybrid-
PVDA membrane (Amersham Life Sciences) via a semi-
dry electrophoretic transfer method, and treated with
20% methanol in a Tris-glycine buffer (25 mM Tris-HCl,
pH 8.0, 0.2 M glycine, 0.1% SDS). After blocking with
PBS containing 5% BSA, the membrane was incubated
for immunoblotting analysis with a rabbit anti-myc poly-
clonal antibody (1:100; made in our laboratory) or anti-
myc antibody (1:1,000) at room temperature for 2 h,
followed by incubation with an IRDye 800DX-
conjugated, affinity-purified goat anti-rabbit secondary
antibody (1:1,000; Rockland). Signals were detected
using the Odyssey Infrared Imaging System (LI-COR
Biosciences). β-actin was used as a loading control.
Identification of CNVs
Array-based comparative genomic hybridization (aCGH)
was performed using Agilent 244-k arrays as previously
described [23]. CNVs that were present in the matching
normal sample were filtered, and the remaining CNVs
were regarded as somatic variants.
RNA interference
Three siRNAs directed against five target genes were
designed on the Whitehead Institute Web Server (http://
jura.wi.mit.edu/bioc/siRNAext/) and chemically synthesized
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regions of each gene. The siRNA sequences are shown in
Additional file 1: Table S6. In addition, siRNA-NC (5′-
GAGUUAAAGUCAAAGUGACTT-3′ and 5′-GUCACU
UUGACUUUAACUCTT-3′) was also synthesized. The
siRNAs were transfected into the HCC cell lines, and cell
growth was monitored. For siRNA transfection, 3 × 103
HCC cells per well were seeded into 96-well plates. When
the cells reached 30% to 50% confluence, they were trans-
fected with synthetic siRNAs at a final concentration of 50
nM using the Lipofectamine 2000 Transfection Reagent
(Invitrogen) according to the manufacturer’s instructions.
Cell proliferation analysis
The cells were cultured for 7 days, and cell viability was
measured using the ACEA RTCA kit (ACEA Biosciences,
San Diego, CA, USA). A microelectronic cell sensor system
was used to confirm the number of living cells. NSCLC
cells (1 × 104) were seeded into each sensor-containing well
(19.6-mm2 surface with 150 mL of medium) of the microti-
ter plates. The electronic sensors provided a continuous
(every 6 h), quantitative measurement of the cell index
(reflecting the surface area covered by the cells) in each
well. Cell growth was measured every 6 h for 96 to 144 h,
and cell indexes were recorded for each well at all time
points to assess cell viability. All experiments were inde-
pendently repeated at least three times.
Soft agar colony formation
For soft agar colony formation assays in 24-well plates,
2 × 104 cells were plated and grown on plates containing
1% base agar and 0.5% top agar. The plated cells were in-
cubated at 37°C for 21 days. The plates were stained with
0.005% crystal violet for 1 h, and colonies were counted
under a dissecting microscope. All experiments were inde-
pendently repeated at least three times.
Data availability
The sequencing and processed data have been deposited in
the NCBI SRA and GEO database under the accession
number SRA092219 and GSE54141. All the UPLC-MS/MS
raw data were deposited in figshare database (http://dx.doi.
org/10.6084/m9.figshare.1117723).
Additional files
Additional file 1: All supplemental tables (Tables S1 to S10) and
corresponding captions.
Additional file 2: All supplemental figures (Figures S1 to S8) and
corresponding legends.
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